Covered recipient · General Payments record
YURI MCCLENDON
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,384.06
- Reported across 67 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $308.28 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $72.79 | 3 |
| ABBVIE INC. | $68.42 | 3 |
| PFIZER INC. | $55.35 | 3 |
| Acerta Pharma LLC | $33.39 | 2 |
| Dynavax Technologies Corporation | $19.70 | 1 |
| Amgen Inc. | $16.49 | 1 |
| Lilly USA, LLC | $14.72 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.15 | 1 |
| Exact Sciences Corporation | $13.27 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $18.11 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104995839 | CMS |
| ABBVIE INC. | $24.50 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104995841 | CMS |
| ABBVIE INC. | $25.81 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104995843 | CMS |
| Amgen Inc. | $16.49 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115914305 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.08 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105434541 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.31 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104366343 | CMS |
| Dynavax Technologies Corporation | $19.70 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1082152559 | CMS |
| Exact Sciences Corporation | $13.27 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114779818 | CMS |
| Lilly USA, LLC | $14.72 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135485429 | CMS |
| Novo Nordisk Inc | $16.47 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097070480 | CMS |
| Novo Nordisk Inc | $24.59 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097014240 | CMS |
| Novo Nordisk Inc | $31.73 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096594768 | CMS |
| PFIZER INC. | $18.70 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131167053 | CMS |
| PFIZER INC. | $17.75 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131228687 | CMS |
| PFIZER INC. | $18.90 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131043702 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.15 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137632346 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.